澳大利亚年轻女性常规沙眼衣原体筛查中的人乳头瘤病毒流行率监测
研究评估在16-24岁女性常规沙眼衣原体筛查残留标本中进行HPV检测的可行性,采集362份标本并获取357人疫苗接种史。四价疫苗靶型(HPV6/11/16/18)总流行率2.8%(1.5-5.1%),不同接种状态间无差异(p=0.729);九价疫苗额外靶型(HPV31/33/45/52/58)流行率19.3%(15.6-23.8%)。作者认为该方法简单可行,可用于监测循环基因型。
要点
- 362份残留标本中四价疫苗靶型流行率2.8%,接种状态间无差异(p=0.729)
- 九价疫苗额外靶型流行率19.3%,致癌型HPV总检出率46.8%
- 残留衣原体标本HPV检测可作为监测疫苗影响的可行方法
核心结论
- 对残留衣原体标本进行HPV检测提供了一种简单、可行的循环基因型监测方法,大规模应用可及时评估九价疫苗对尚未符合宫颈筛查条件年轻女性的影响。
研究设计与样本
- 研究收集2018年4月至7月期间来自维多利亚州和新南威尔士州三个病理实验室的16-24岁女性衣原体检测残留标本,并进行HPV基因分型。
主要发现
- 共采集362份残留标本,其中60.2%为宫颈拭子。
- 获取357名女性(98.6%)的人口学数据和疫苗接种史,平均年龄21.8岁(SD 2.0)。
- 65.6%的女性完成全程接种,9.8%部分接种,24.7%未接种。
- 86.0%居住在大城市,35.9%处于社会经济优势最高五分位,衣原体阳性率为7.8%。
- 四价疫苗靶型(HPV6/11/16/18)总流行率为2.8%(95% CI 1.5-5.1%),不同接种状态间无差异(p=0.729)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Australia has recently implemented major changes in cervical cancer prevention policies including introduction of primary human papillomavirus (HPV) screening starting at age 25, and replacement of the quadrivalent HPV vaccine with the nonavalent vaccine in the national school-based program. We assessed the feasibility and utility of conducting HPV testing in residual clinical specimens submitted for routine Chlamydia trachomatis screening, as a means of tracking HPV vaccine program impact among young sexually active women. METHODS: De-identified residual specimens from women aged 16-24 years submitted for chlamydia testing were collected from three pathology laboratories in Victoria and New South Wales. Limited demographic information, and chlamydia test results were also collected. Patient identifiers were sent directly from the laboratories to the National HPV Vaccination Program Register, to obtain HPV vaccination histories. Samples underwent HPV genotyping using Seegene Anyplex II HPV 28 assay. RESULTS: Between April and July 2018, 362 residual samples were collected, the majority (60.2%) of which were cervical swabs. Demographic data and vaccination histories were received for 357 (98.6%) women (mean age 21.8, SD 2.0). Overall, 65.6% of women were fully vaccinated, 9.8% partially, and 24.7% unvaccinated. The majority (86.0%) resided in a major city, 35.9% were classified in the upper quintile of socioeconomic advantage and chlamydia positivity was 7.8%.The prevalence of quadrivalent vaccine-targeted types (HPV6/11/16/18) was 2.8% (1.5-5.1%) overall with no differences by vaccination status (p = 0.729). The prevalence of additional nonavalent vaccine-targeted types (HPV31/33/45/52/58) was 19.3% (15.6-23.8%). One or more oncogenic HPV types were detected in 46.8% (95% CI 41.6-52.0%) of women. CONCLUSIONS: HPV testing of residual chlamydia specimens provides a simple, feasible method for monitoring circulating genotypes. Applied on a larger scale this method can be utilised to obtain a timely assessment of nonavalent vaccine impact among young women not yet eligible for cervical screening.
引用
- Shilling H, Murray G, Brotherton JML, et al. Monitoring human papillomavirus prevalence among young Australian women undergoing routine chlamydia screening. Vaccine. 2019. PMID: 31767467. doi:10.1016/j.vaccine.2019.11.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。